J&J ups profit outlook, boosted by blockbuster drug Stelara
Investors now focus on how the company will reach its targets before biosimilars are retailed
17 October 2023 - 17:21
byBhanvi Satija and Sriparna Roy
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Bengaluru — Johnson & Johnson (J&J) on Tuesday raised its 2023 profit forecast, helped by resilient demand for its blockbuster anti-inflammatory drug Stelara and recorded a $21bn gain from the spin-off of its consumer health unit.
The company’s shares were up about 1% in premarket trading.
Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57bn in drug sales by 2025. The company is facing a potential slowdown in sales of its arthritis drug Stelara after the launch of biosimilars.
J&J finalised the biggest shake-up in its 137-year history in August through an exchange of its shares with former consumer health unit Kenvue, leaving the pharmaceutical giant with a reduced 9.5% stake in its former unit.
J&J reported third-quarter total sales of $21.35bn, compared with analysts’ estimates of $21.04bn, according to LSEG data.
Stelara brought in sales of $2.86bn, above estimates of $2.61bn. The company’s innovative medicine unit reported quarterly sales of $13.89bn, of which Stelara accounted for more than 20%.
J&J has signed settlements to delay the launch of copycat rivals of Stelara until 2025, which may help the drug continue to significantly contribute to the company’s sales.
Sales at J&J’s medical device unit came in at $7.46bn for the quarter, missing estimates of $7.58bn.
Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.
The company posted a third-quarter profit of $1.69 per share, compared with $1.62 per share a year earlier.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
J&J ups profit outlook, boosted by blockbuster drug Stelara
Investors now focus on how the company will reach its targets before biosimilars are retailed
Bengaluru — Johnson & Johnson (J&J) on Tuesday raised its 2023 profit forecast, helped by resilient demand for its blockbuster anti-inflammatory drug Stelara and recorded a $21bn gain from the spin-off of its consumer health unit.
The company’s shares were up about 1% in premarket trading.
Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57bn in drug sales by 2025. The company is facing a potential slowdown in sales of its arthritis drug Stelara after the launch of biosimilars.
J&J finalised the biggest shake-up in its 137-year history in August through an exchange of its shares with former consumer health unit Kenvue, leaving the pharmaceutical giant with a reduced 9.5% stake in its former unit.
J&J reported third-quarter total sales of $21.35bn, compared with analysts’ estimates of $21.04bn, according to LSEG data.
Stelara brought in sales of $2.86bn, above estimates of $2.61bn. The company’s innovative medicine unit reported quarterly sales of $13.89bn, of which Stelara accounted for more than 20%.
J&J has signed settlements to delay the launch of copycat rivals of Stelara until 2025, which may help the drug continue to significantly contribute to the company’s sales.
Sales at J&J’s medical device unit came in at $7.46bn for the quarter, missing estimates of $7.58bn.
Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.
The company posted a third-quarter profit of $1.69 per share, compared with $1.62 per share a year earlier.
Reuters
Competition watchdog probes J&J TB drug pricing
Covid vaccine contracts hold SA to ransom
Health department hands over Covid-19 contracts to NGO
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
AstraZeneca’s Tagrisso cancer drug throws down the gauntlet for J&J rival
Deadline looms for health department to hand over Covid-19 vaccine contracts
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.